Evidence map›Paper›PMID 40750653›Full record

ReviewNPJ digital medicine2025

Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies.

Ulrike Weirauch, Markus Kreuz, Colin Birkenbihl, Miriam Alb, Maria Quaranta, Laurence Calzone, Sophia Orozco-Ruiz, Stefanie Binder, Luise Fischer, Solène Clavreul and 37 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in NPJ digital medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

47 authors.

Ulrike WeirauchFraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany.
Markus KreuzFraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany.
Colin BirkenbihlFraunhofer Institute for Algorithms and Scientific Computing SCAI, Sankt Augustin, Germany.
Miriam AlbDepartment of Internal Medicine II, Chair of Cellular Immunotherapy, University Hospital Würzburg, Würzburg, Germany.
Maria QuarantaInformation Technology for Translational Medicine (ITTM) S.A., Esch-sur-Alzette, Luxembourg.
Laurence CalzoneInstitut Curie, INSERM, U 1331, Mines Paris Tech, PSL Research University, Paris, France.
Sophia Orozco-RuizInstitut Curie, INSERM, U 1331, Mines Paris Tech, PSL Research University, Paris, France.
Stefanie BinderInstitute for Clinical Immunology, University Hospital of Leipzig, Leipzig, Germany.
Luise FischerDepartment of Hematology, Hemostaseology and Cellular Therapy, University Hospital of Leipzig, Leipzig, Germany.
Solène ClavreulMyeloma Patients Europe AISBL, Brussels, Belgium.
Morine MaguriMyeloma Patients Europe AISBL, Brussels, Belgium.
Maximilian FerleFraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany.
Michael RadeFraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany.
Guillaume AzariasTriNetX Oncology GmbH, Freiburg, Germany.
Jay R HydrenHealthTree Foundation Inc., Lehi, UT, USA.
Jakub JamarikCREATIC, Faculty of Medicine, Masaryk University, Brno, Czechia.
Daniel SchwarzCREATIC, Faculty of Medicine, Masaryk University, Brno, Czechia.
Zsolt SebestyenCenter for Translational Immunology and Department of Hematology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Jurgen KuballCenter for Translational Immunology and Department of Hematology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Georg PoppFraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany.
Chloé AntoineResearch Center Information, Law and Society, University of Namur, Namur, Belgium.
Manon KnockaertResearch Center Information, Law and Society, University of Namur, Namur, Belgium.
Clara T SchoederFraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany.
David FandreiFraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany.
Carmen SangesDepartment of Internal Medicine II, Chair of Cellular Immunotherapy, University Hospital Würzburg, Würzburg, Germany.
Vaclovas RadvilasEuropean Society for Blood and Marrow Transplantation (EBMT), Leiden, The Netherlands.
Nico GagelmannDepartment of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Markus RückertTriNetX Oncology GmbH, Freiburg, Germany.
Olaf PenackDepartment of Hematology, Oncology and Tumorimmunology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Stephan FrickeFraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany.
Andreas SchmidtSingleron Biotechnologies GmbH, Cologne, Germany.
Carol WardF. Hoffmann-LaRoche AG, Basel, Switzerland.
Carl SteinbeisserCollaborate Project Management, Munich, Germany.
Jean-Marc Van GyseghemResearch Center Information, Law and Society, University of Namur, Namur, Belgium.
Anna NiarakisMolecular, Cellular and Developmental Biology Unit (MCD), Centre de Biologie Integrative (CBI), University of Toulouse, UPS, CNRS, Toulouse, France.
Laurent GarderetHematology and Cellular Therapy Department, Hopital Pitié Salpêtrière APHP, Sorbonne Université, Paris, France.
Michael HudecekDepartment of Internal Medicine II, Chair of Cellular Immunotherapy, University Hospital Würzburg, Würzburg, Germany.
Thomas NeumuthInnovation Center Computer Assisted Surgery, Universität Leipzig, Leipzig, Germany.
Uwe PlatzbeckerDepartment of Hematology, Hemostaseology and Cellular Therapy, University Hospital of Leipzig, Leipzig, Germany.
Ulrike KöhlFraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany.
Regina DemlovaCREATIC, Faculty of Medicine, Masaryk University, Brno, Czechia.
Andreas KremerInformation Technology for Translational Medicine (ITTM) S.A., Esch-sur-Alzette, Luxembourg.
Stefan FrankeInnovation Center Computer Assisted Surgery, Universität Leipzig, Leipzig, Germany.
Holger FröhlichFraunhofer Institute for Algorithms and Scientific Computing SCAI, Sankt Augustin, Germany.
Maximilian MerzFraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany.
Kristin ReicheFraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany. kristin.reiche@izi.fraunhofer.de.
CERTAINTY Consortium

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
European Union 101136379NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

In (immune)oncology, virtual twins (VTs) offer patient-individual decision support. Nevertheless, current VTs do not incorporate the unique properties of engineered adoptive cellular immunotherapies (eACIs). Here, we outline the minimal design specifications for VTs for engineered ACIs (eACI-VTs) to model the complex interplay between cell product and patient physiology. We motivate utilizing VTs in eACIs to provide decision support and reflect on how eACI-VTs can support the widespread use of eACIs.

Identifiers

PMID40750653
PMCPMC12316993

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.